Shots:

• AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated P-III study to assess Farxiga (dapagliflozin) + SOC vs PBO in patients hospitalized with COVID-19 having a risk of developing serious complications like organ failure
• The primary outcome of the study is time to the first occurrence of death from any cause or new/worsened organ dysfunction via 30days of follow-up. The P-III DARE-19 study is enrolling patients in the US and EU with an aim to recruit ~900 patients
• Farxiga (PO- QD) is an SGLT2 inhibitor indicated in adults for the treatment of insufficiently controlled T2D as both monothx. and combination therapy as an adjunct to diet and exercise to improve glycemic control- weight loss and BP reduction

Click here ­to­ read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca